Diversify Wealth Management LLC Buys 3,564 Shares of Amgen Inc. (NASDAQ:AMGN)

Diversify Wealth Management LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 52.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,373 shares of the medical research company's stock after purchasing an additional 3,564 shares during the period. Diversify Wealth Management LLC's holdings in Amgen were worth $2,993,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Pinney & Scofield Inc. purchased a new position in shares of Amgen during the 4th quarter worth approximately $26,000. First Pacific Financial boosted its position in shares of Amgen by 304.5% in the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock worth $28,000 after purchasing an additional 67 shares in the last quarter. Ritter Daniher Financial Advisory LLC DE boosted its position in shares of Amgen by 66.2% in the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock worth $33,000 after purchasing an additional 51 shares in the last quarter. Atala Financial Inc bought a new stake in shares of Amgen in the 4th quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new stake in shares of Amgen in the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 76.50% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMGN. William Blair reissued an "outperform" rating on shares of Amgen in a research report on Tuesday, June 24th. Cantor Fitzgerald reissued a "neutral" rating and issued a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Piper Sandler reaffirmed an "overweight" rating and issued a $328.00 price objective on shares of Amgen in a research report on Friday, June 27th. Royal Bank Of Canada lowered their price objective on Amgen from $324.00 to $320.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. Finally, Erste Group Bank cut Amgen from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Amgen has a consensus rating of "Hold" and an average price target of $307.82.

Amgen Trading Down 1.7%

Shares of Amgen stock opened at $295.27 on Friday. The firm has a market cap of $158.77 billion, a price-to-earnings ratio of 26.94, a PEG ratio of 2.72 and a beta of 0.49. The business has a 50-day moving average price of $283.56 and a 200-day moving average price of $287.97. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 8.70. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.11% and a net margin of 17.39%. The business had revenue of $8.15 billion during the quarter, compared to analyst estimates of $8.05 billion. During the same quarter in the previous year, the business earned $3.96 earnings per share. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. Equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Insider Activity

In related news, SVP Rachna Khosla sold 1,500 shares of the business's stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president owned 8,162 shares in the company, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.76% of the company's stock.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.